Figure 3 | Scientific Reports

Figure 3

From: The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression

Figure 3

INCB057643 and selinexor synergize to increase HGBCL-DH with wild-type TP53 cell death. (A) Analysis of the viability of OCI-LY19, EJ and Pfeiffer cells exposed to INCB057643 and selinexor alone or in combination for 72 h. (B) The CI values indicate that INCB057643 and selinexor acted synergistically to reduce the viability of OCI-LY19, EJ and Pfeiffer cells. (C) Compared with either monotherapy, INCB057643 and selinexor synergistically enhanced apoptosis in OCI-LY19, EJ and Pfeiffer cells. (D) Analysis of the CI values of INCB057643 combined with selinexor in OCI-LY19, EJ and Pfeiffer cells.

Back to article page